COMMUNIQUÉS West-GlobeNewswire

Rectify Pharmaceuticals Presents Translational Data on RTY-406 at AASLD 2026 Liver Meeting
05/11/2026
Presentation highlights preclinical characterization of RTY-406, an oral, once-daily investigational therapy targeting underlying drivers of hepatobiliary diseases BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rectify [...]
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
05/11/2026
In real-world studies, up to 93% of patients experienced improvement or stabilization in liver stiffness with ultrasound elastography, with many patients moving into lower liver stiffness categories one year after [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
05/11/2026
Bagsværd, Denmark. 5 November 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
KFSH Riyadh Earns Davos Healthcare’s Global Elite Five-Star Medallion, Ranking Among Top 5% of Evaluated Hospitals
05/11/2026
RIYADH, Saudi Arabia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) in Riyadh has received Davos Healthcare’s Global Elite Five-Star Medallion, the highest distinction in [...]
Former Ministers and a Former Head of Government Press the G20 to Put Brain Health Inside Its AI Agenda
05/11/2026
Global Communiqué urges prevention as the foundation of Alzheimer’s policy, and a standing G20 mechanism so leadership on brain health outlasts individual governments WASHINGTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Former [...]
Every like and share supports care for Saskatchewan kids
05/11/2026
Before you scroll past, consider this: your click could bring life-saving equipment to kids in Saskatchewan. SASKATOON, Saskatchewan, Nov. 05, 2026 (GLOBE NEWSWIRE) -- This November, Saskatchewan Blue Cross is once [...]
Compounded Semaglutide Cost per Month Stays the Same From 0.25 mg to 2.4 mg at NexLife
05/11/2026
Standard compounded semaglutide injections prescribed through NexLife are $119 a month on the 12-month plan or $139 month to month at every weekly dose from 0.25 mg to 2.4 mg; standard compounded tirzepatide injections [...]
Kraig Labs Advances Commercial Spider Silk Production with New Customer Shipments and New Silkworm Research
05/11/2026
DENVER, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews )— Kraig Biocraft Laboratories (OTCQB: KBLB) recently shipped its first commercial order of recombinant spider silk yarn to a globally recognized sportswear [...]
Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results
05/11/2026
Press Release – No. 22 / 2026 Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Copenhagen, Denmark, November 5, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR- [...]
Genmab Announces Financial Results for the Nine Months of 2026
05/11/2026
November 5, 2026 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2026 Highlights Epcoritamab approved in Europe (as TEPKINLY ® ) and Japan (as EPKINLY ® ) in combination with R² for the [...]
Osteal Therapeutics Announces Three Scientific Presentations Related to the APEX Clinical Trial Program at the 2026 AAHKS Annual Meeting
05/11/2026
Presentations will address 24-month treatment outcomes, systemic antibiotic exposure, and new treatment strategies for recalcitrant periprosthetic joint infection DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Osteal [...]
Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
05/11/2026
FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months FORT LEE [...]
Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL
05/11/2026
Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting ® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGY À la semaine 52, 85,3 % des patients recevant [...]
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
05/11/2026
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® [...]
RAMSAY SANTE : résultats intermédiaires au 30 septembre 2026
05/11/2026
COMMUNIQUÉ DE PRESSE Paris, 5 novembre 2026 Résultats trimestriels non audités à fin septembre 2026 Ramsay Santé affiche une solide performance au premier trimestre, avec une croissance continue de son chiffre d’ [...]
RAMSAY SANTE : Unaudited interim results at the end of September 2026
05/11/2026
PRESS RELEASE Paris, 5 th November 2026 Unaudited interim results at the end of September 2026 Ramsay Santé delivers solid first-quarter performance, with continued revenue growth and improved operational performance [...]
Significant growth in both revenue and earnings
05/11/2026
ANNOUNCEMENT NR. 325 5 November 2026 Trading statement for Q1 2026/27 (1 July – 30 September 2026) Significant growth in both revenue and earnings Revenue was up by 28% in Q1 2026/27 to DKK 160.0 million from DKK 124.6 [...]
GENFIT : Information financière du troisième trimestre 2026 et point sur les activités de la Société
05/11/2026
La trésorerie et les équivalents de trésorerie s’élèvent à 95,6 millions d’euros au 30 septembre 2026 et permettent un financement des activités au-delà de fin 2028. La croissance attendue des revenus futurs, combinée [...]
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
05/11/2026
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward [...]

Pages